Literature DB >> 22472959

Cutaneous and subcutaneous pleomorphic liposarcoma: a clinicopathologic study of 29 cases with evaluation of MDM2 gene amplification in 26.

Jerad M Gardner1, Monisha Dandekar, Dafydd Thomas, John R Goldblum, Sharon W Weiss, Steven D Billings, David R Lucas, Jonathan B McHugh, Rajiv M Patel.   

Abstract

Pleomorphic liposarcoma (PL) is an uncommon form of liposarcoma that rarely occurs in the skin and subcutis. As its behavior in this setting is incompletely characterized, we undertook a study of a series of superficial PLs, defined as those arising or based primarily in the dermis and/or subcutis without involvement of deep structures. In addition, MDM2 gene amplification, a diagnostic signature of well-differentiated/dedifferentiated liposarcoma (WDL/DL), was evaluated to address the recent observation that this gene is amplified within PL-like areas in DL. PLs were obtained from institutional and consultation files (n=29). Cases were evaluated with respect to age, sex, location (dermis, dermis and subcutis, subcutis), size, predominant pattern (pleomorphic spindled or epithelioid), extent of lipogenic differentiation, and tumor necrosis. MDM2 amplification was analyzed using FISH on formalin-fixed, paraffin-embedded material in 26 cases. Patients ranged in age from 5 to 93 years (M:F=1.4:1). Tumors were located on the extremity (n=15), trunk (n=7), and head and neck (n=7) and involved the dermis (n=4), dermis and subcutis (n=10), and subcutis (n=15). Tumor size ranged from 0.8 to 15 cm (median=2 cm). All were mitotically active high-grade sarcomas [FNCLCC grade 2 (n=23) or 3 (n=6)] with either a pleomorphic spindled (n=24) or an epithelioid pattern (n=5) with variable extent of lipogenic differentiation [<25% (n=15), 25% to 50% (n=9), >50% (n=5)]. Necrosis was present in 3 cases. MDM2 gene amplification was present in 3 of 26 cases. Follow-up information in 24 cases (range=1 to 192 mo; median=48 mo; mean=59 mo) revealed local recurrences (4/24) but no metastasis or death from disease. We conclude that cutaneous and subcutaneous PLs, despite their high grade, have a much more favorable outcome compared with their deep-seated counterparts, most likely attributed to their small size and superficial location. The low incidence of MDM2 gene amplification in our series indicates that most superficial PLs are unrelated to WDL/DL. PL likely evolves by way of more than 1 molecular pathway.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22472959     DOI: 10.1097/PAS.0b013e3182517b96

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

1.  Liposarcoma in children and young adults: a clinicopathologic and molecular study of 23 cases in one of the largest institutions of China.

Authors:  Ran Peng; Nan Li; Ting Lan; Huijiao Chen; Tianhai Du; Xin He; Min Chen; You Xie; Zhang Zhang; Wei Zhao; Hongying Zhang
Journal:  Virchows Arch       Date:  2021-03-18       Impact factor: 4.064

Review 2.  Malignant Superficial Mesenchymal Tumors in Children.

Authors:  Philippe Drabent; Sylvie Fraitag
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

Review 3.  Soft Tissue Special Issue: Selected Topics in the Pathology of Adipocytic Tumors.

Authors:  Wonwoo Shon; Steven D Billings
Journal:  Head Neck Pathol       Date:  2020-01-16

4.  Challenging dedifferentiated liposarcoma identified by MDM2-amplification, a report of two cases.

Authors:  Suvi Lokka; Andreas H Scheel; Sebastian Dango; Katja Schmitz; Rudolf Hesterberg; Josef Rüschoff; Hans-Ulrich Schildhaus
Journal:  BMC Clin Pathol       Date:  2014-07-28

Review 5.  Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

Authors:  Alessandro De Vita; Laura Mercatali; Federica Recine; Federica Pieri; Nada Riva; Alberto Bongiovanni; Chiara Liverani; Chiara Spadazzi; Giacomo Miserocchi; Dino Amadori; Toni Ibrahim
Journal:  Onco Targets Ther       Date:  2016-10-11       Impact factor: 4.147

6.  Combined cutaneous sarcoma: pleomorphic liposarcoma and conventional osteosarcoma-the so-called malignant mesenchymoma.

Authors:  David Parada; Karla B Peña
Journal:  Case Rep Pathol       Date:  2012-10-02

Review 7.  Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.

Authors:  Jocelyn Y Hsu; Nathan D Seligson; John L Hays; Wayne O Miles; James L Chen
Journal:  JCO Precis Oncol       Date:  2022-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.